ProCE Banner Activity

ADAURA Trial Update: Adjuvant Osimertinib vs Placebo After Complete Resection in Stage IB-IIIA EGFR-Mutated NSCLC

Slideset Download
Conference Coverage
Updated results from the phase III ADAURA trial showed a clinically meaningful improvement in DFS with adjuvant osimertinib vs placebo in fully resected stage IB-IIIA EGFR-mutated NSCLC.

Released: September 19, 2022

Expiration: September 18, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.